FIG. 1.

Flow cytometry analysis of CD1b expression in AMNC pretreated with GM-CSF (10 IU/ml) plus IL-4 (200 IU/ml) alone (A) or with RFP at 2 (B) or 10 (C) μg/ml. Analysis was performed after 3 days of culture. Isotype-matched control MAb results are shown as a faint profile, and CD1b results are shown as a solid profile. Percent values relative to cells positive for CD1b molecules (range of four separate experiments; data not shown) were as follows: untreated AMNC, 1 to 3%; AMNC treated with IL-4 alone, 13 to 15%; AMNC treated with GM-CSF alone, 50 to 53%; AMNC treated with GM-CSF plus RFP (2 or 10 μg/ml), 60 to 70%. Exposure of AMNC to RFP (2 or 10 μg/ml) did not modify the limited percentage of CD1b-positive cells in the untreated or IL-4-treated groups.